These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32941647)

  • 1. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
    Weng WK; Arai S; Rezvani A; Johnston L; Lowsky R; Miklos D; Shizuru J; Muffly L; Meyer E; Negrin RS; Wang E; Almazan T; Million L; Khodadoust M; Li S; Hoppe RT; Kim YH
    Blood Adv; 2020 Sep; 4(18):4474-4482. PubMed ID: 32941647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome.
    Morris SL; Thomas BR; Palanicawandar R; Whittaker S; Child F; Wain M; Sim V; Szydlo R; Mangar S; Olavarria E; Lozano Cerrada S; Muzamil A; Kanfer E
    Bone Marrow Transplant; 2024 Jun; 59(6):874-879. PubMed ID: 38472408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
    Duvic M; Donato M; Dabaja B; Richmond H; Singh L; Wei W; Acholonu S; Khouri I; Champlin R; Hosing C
    J Clin Oncol; 2010 May; 28(14):2365-72. PubMed ID: 20351328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
    Hsu J; Artz A; Mayer SA; Guarner D; Bishop MR; Reich-Slotky R; Smith SM; Greenberg J; Kline J; Ferrante R; Phillips AA; Gergis U; Liu H; Stock W; Cushing M; Shore TB; van Besien K
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):359-365. PubMed ID: 29128555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas.
    de Masson A; Beylot-Barry M; Bouaziz JD; Peffault de Latour R; Aubin F; Garciaz S; d'Incan M; Dereure O; Dalle S; Dompmartin A; Suarez F; Battistella M; Vignon-Pennamen MD; Rivet J; Adamski H; Brice P; François S; Lissandre S; Turlure P; Wierzbicka-Hainaut E; Brissot E; Dulery R; Servais S; Ravinet A; Tabrizi R; Ingen-Housz-Oro S; Joly P; Socié G; Bagot M;
    Haematologica; 2014 Mar; 99(3):527-34. PubMed ID: 24213148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.
    Isufi I; Seropian S; Gowda L; Wilson LD; Roberts K; Girardi M; Perreault S; Foss F
    Leuk Lymphoma; 2020 Dec; 61(12):2955-2961. PubMed ID: 32643494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution.
    Hosing C; Bassett R; Dabaja B; Talpur R; Alousi A; Ciurea S; Popat U; Qazilbash M; Shpall EJ; Oki Y; Nieto Y; Pinnix C; Fanale M; Maadani F; Donato M; Champlin R; Duvic M
    Ann Oncol; 2015 Dec; 26(12):2490-5. PubMed ID: 26416896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome.
    Shiratori S; Fujimoto K; Nishimura M; Hatanaka KC; Kosugi-Kanaya M; Okada K; Sugita J; Shigematsu A; Hashimoto D; Endo T; Kondo T; Abe R; Hashino S; Matsuno Y; Shimizu H; Teshima T
    Hematol Oncol; 2016 Mar; 34(1):9-16. PubMed ID: 25312300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis.
    Ueda Oshima M; Storer BE; Qiu H; Chauncey T; Asch J; Boyer MW; Giaccone L; Flowers M; Mielcarek M; Storb R; Maloney DG; Sandmaier BM
    Transplant Cell Ther; 2021 Feb; 27(2):163.e1-163.e7. PubMed ID: 33830025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
    Spinner MA; Kennedy VE; Tamaresis JS; Lavori PW; Arai S; Johnston LJ; Meyer EH; Miklos DB; Muffly LS; Negrin RS; Rezvani AR; Shizuru JA; Weng WK; Hoppe RT; Strober S; Lowsky R
    Blood Adv; 2019 Aug; 3(16):2454-2464. PubMed ID: 31427277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas.
    Montes de Oca C; Castagna L; De Philippis C; Bramanti S; Schiano JM; Pagliardini T; Collignon A; Harbi S; Mariotti J; Granata A; Maisano V; Furst S; Legrand F; Chabannon C; Carlo-Stella C; Santoro A; Blaise D; Devillier R
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2299-2305. PubMed ID: 32822845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.
    Sauter CS; Barker JN; Lechner L; Zheng J; Devlin SM; Papadopoulos EB; Perales MA; Jakubowski AA; Goldberg JD; Koehne G; Ceberio I; Giralt S; Zelenetz AD; Moskowitz CH; Castro-Malaspina H
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):354-60. PubMed ID: 24315843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Duarte RF; Canals C; Onida F; Gabriel IH; Arranz R; Arcese W; Ferrant A; Kobbe G; Narni F; Deliliers GL; Olavarría E; Schmitz N; Sureda A
    J Clin Oncol; 2010 Oct; 28(29):4492-9. PubMed ID: 20697072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
    Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.